MedTrace Logo

ACCEL-LOADING-ACS Study

NCT01354808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2013-09-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major adverse cardiovascular events, platelet activation, inflammation and myonecrosis in patients with non-ST-elevation acute coronary syndrome (ACS)undergoing percutaneous coronary intervention (PCI).

Conditions

  • Platelet Aggregation Inhibitors
  • Anti-inflammatory Agent
  • Myocardial Reperfusion Injury

Interventions

DRUG

Dual Anti-Platelet Therapy (DAPT)

* Loading: aspirin 300mg + clopidogrel 600mg * Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month

DRUG

Triple Anti-Platelet Therapy (TAPT)

* Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg * Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month

Sponsors & Collaborators

  • Gyeongsang National University Hospital

    lead OTHER

Principal Investigators

  • Kyounghoon Lee, MD, PhD · Gil hospital

  • Jae-Hyeong Park, MD, PhD · Chungnam National University Hospital

  • Keun-Ho Park, MD · Heart Center of Chonnam National University Hospital

  • Jon Suh, MD, PhD · Soon Chun Hyang University

  • Sang-Yong Yoo, MD, PhD · Gangneung Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354808 on ClinicalTrials.gov